Related Experiment Video

Updated: Sep 14, 2026

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts
07:13

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts

Published on: May 13, 2014

[Mechanism of multidrug resistance caused by retinoic acid]

C Li1, J Fu

  • 1Childrens' Hospital, Shenzhen 518026, China.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|February 28, 2002
PubMed
Abstract

Insights

All-trans retinoic acid (ATRA) increases multidrug resistance (MDR) in hepatoblastoma cells by upregulating P-glycoprotein (P-gp). Interleukin-4 (IL-4) enhances drug sensitivity, potentially via p53 or bcl-2 pathways.

Area of Science:

  • Hepatocellular carcinoma research
  • Cancer drug resistance mechanisms
  • Molecular oncology

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • All-trans retinoic acid (ATRA) is used in treating certain cancers, but its effect on MDR is not fully understood.
  • Interleukin-4 (IL-4) is an immunomodulatory cytokine with potential anti-cancer effects.

Purpose of the Study:

  • To investigate the regulatory mechanisms of multidrug resistance (MDR) induced by all-trans retinoic acid (ATRA).
  • To evaluate the impact of ATRA and IL-4 on the differentiation and drug sensitivity of human hepatoblastoma cells (HepG2).

Main Methods:

  • HepG2 cells were treated with ATRA and IL-4 to assess cell differentiation.
  • Flow cytometry and in situ hybridization were used to measure the expression of key proteins and mRNA (p53, bcl-2, P-gp, c-jun, c-myc).
  • MTT assays evaluated the sensitivity of tumor cells to chemotherapeutic agents.

Main Results:

  • ATRA induced differentiation and increased drug resistance (resistant factors: 1.6-3.1), significantly upregulating P-glycoprotein (P-gp) expression.
  • IL-4 promoted differentiation and enhanced drug sensitivity (reversal index: 4-17), markedly inhibiting P-gp expression.
  • Both ATRA and IL-4 downregulated c-jun and c-myc mRNA; p53 and bcl-2 expression were modulated by IL-4 but not ATRA.

Conclusions:

  • Increased P-gp expression due to ATRA is a potential factor in MDR.
  • Cell differentiation and c-jun/c-myc mRNA levels may not directly correlate with ATRA/IL-4-induced drug sensitivity changes.
  • p53 or bcl-2 may play a role in regulating drug sensitivity during differentiation.

More Related Videos

Optimized Automated Analysis of Live Neuronal Mitochondria Homeostasis Modulation by Isoform-Specific Retinoic Acid Receptors08:33

Optimized Automated Analysis of Live Neuronal Mitochondria Homeostasis Modulation by Isoform-Specific Retinoic Acid Receptors

Published on: July 28, 2023

Quantitative Analysis of Dietary Vitamin A Metabolites in Murine Ocular and Non-Ocular Tissues Using High-Performance Liquid Chromatography05:03

Quantitative Analysis of Dietary Vitamin A Metabolites in Murine Ocular and Non-Ocular Tissues Using High-Performance Liquid Chromatography

Published on: December 27, 2024

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...